Fundraising Fox
Port Therapeutics
Founded 2021 · 5 employees on LinkedIn · 1 known investors
Find your way into Port Therapeutics
Sign up to see every warm intro you have to Port Therapeutics
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Port Therapeutics team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Port Therapeutics is a company focused on cancer immunotherapy development.
Founders & leadership
SA
Steve AltschulerExecutive ChairDr. Altschuler is Managing Director of Healthcare Ventures at Ziff Capital Partners, where he focuses on machine learning applications in cellular and molecular sciences. He cofounded Spark Therapeutics, which he chaired through its public offering and development of the first FDA- and EMA-approved gene therapy (Luxturna); Spark was acquired by Roche for $4.8B in 2019.
Investors · 1
Founder mafia
2 people who came through Port Therapeutics went on to found or lead other companies.
Frequently asked questions
- What does Port Therapeutics do?
- Port Therapeutics is a company focused on cancer immunotherapy development.
- Who are Port Therapeutics's investors?
- Port Therapeutics's investors include Catalio Capital Management, LP.